Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921076 | 0.88 | ERN1 (0.42) | ERN1PRKDCMEN1KMT2ACA1 | |
| SCHEMBL6556132 | 0.88 | ERN1 (0.42) | ERN1PRKDCMEN1KMT2ACA1 | |
| SCHEMBL14915848 | 0.84 | ALDH1A1 (0.37) | ERN1PRKDCEPAS1MEN1KMT2A | |
| SCHEMBL29249564 | 0.84 | ERN1 (0.39) | ERN1PRKDCGAACA1CA2 | |
| SCHEMBL3150103 | 0.84 | PRKDC (0.34) | ERN1PRKDCLMNAAGTR1 | |
| SCHEMBL31353446 | 0.84 | CA1 (0.33) | ERN1PRKDCLMNAGAAMEN1 | |
| SCHEMBL31673953 | 0.80 | PRKDC (0.52) | ERN1PRKDCLMNAALDH1A1 | |
| SCHEMBL31468224 | 0.80 | ERN1 (0.41) | ERN1PRKDCGAAALDH1A1 | |
| SCHEMBL3185596 | 0.78 | ERN1 (0.50) | ERN1PRKDCLMNAMEN1KMT2A | |
| SCHEMBL23658839 | 0.74 | ERN1 (0.54) | ERN1PRKDCLMNAEPAS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119947718-A | Tricyclic aryl derivatives, and compositions and methods thereof | 昂胜医疗科技公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025061148-A1 | HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-20250000996-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | FORTVITA BIOLOGICS LIMITED (CN) | 2025-01-02 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| WO-2024026129-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| EP-2019675-A1 | METHODS FOR TREATING OR PREVENTING NEOPLASIAS | Merck Frosst Canada Ltd. (CA) | 2009-02-04 | — | — | EP | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| EP-1954683-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO(9,10-D)IMIDAZOLES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007124589-A1 | METHODS FOR TREATING OR PREVENTING NEOPLASIAS | MERCK FROSST CANADA LTD. (CA) | 2007-11-08 | — | — | WO | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
| WO-2007059610-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059611-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000996-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | TOP2A, TOP1, XPA | ERN1 3418/4885PRKDC 292/4885LMNA 986/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | ERN1 3418/4885PRKDC 292/4885LMNA 986/4885 |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | ERN1 2336/4885PRKDC 1309/4885LMNA 947/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ERN1 2456/4885PRKDC 3915/4885LMNA 4356/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | ERN1 856/4885PRKDC 263/4885LMNA 3433/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ERN1 2456/4885PRKDC 3915/4885LMNA 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.